Ligand id: 8182

Name: flibanserin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 38.82
Molecular weight 390.17
XLogP 4.3
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Flibanserin was approved for use as a non-hormonal treatment for pre-menopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD) in August 2015. Flibanserin is approved with a 'Boxed Warning' to highlight the risks of severe hypotension and syncope in patients who drink alcohol whilst taking this drug. Click here to link to ClinicalTrials.gov's full list of Phase III flibanserin trials.
Mechanism Of Action and Pharmacodynamic Effects
Flibanserin targets 5-HT1A and 5-HT2A receptors in selective brain areas [1] and helps to restore the balance between inhibitory serotonin and and excitatory dopamine/noradrenaline effects believed to be requisite for a healthy sexual response.